date,title,source
Oct-18-18,"Consolidated Research: 2018 Summary Expectations for Barnes & Noble, Boot Barn, Endologix, Pilgrim's Pride, OraSure Technologies, and Genesco  Fundamental Analysis, Key Performance Indications",GlobeNewswire
Oct-22-18,"Endologix, Inc. to Announce Third Quarter 2018 Financial Results on November 1, 2018",Business Wire
Oct-24-18,Endologix Announces Public Offering of Common Stock,Business Wire
Oct-25-18,Endologix Announces Pricing of Public Offering of Common Stock,Business Wire
Oct-25-18,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",Benzinga
Oct-29-18,"Endologix, Inc. to Present at Two Investor Conferences in November",Business Wire
Nov-01-18,"Endologix (ELGX) Reports Q3 Loss, Tops Revenue Estimates",Zacks
Nov-01-18,Endologix: 3Q Earnings Snapshot,Associated Press
Nov-01-18,Endologix Reports Third Quarter 2018 Financial Results,Business Wire
Nov-07-18,Edited Transcript of ELGX earnings conference call or presentation 1-Nov-18 8:30pm GMT,Thomson Reuters StreetEvents
Nov-08-18,Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),Business Wire
Nov-12-18,"Report: Developing Opportunities within Mednax, Peabody Energy, NIC, Endologix, MobileIron, and QuinStreet  Future Expectations, Projections Moving into 2018",GlobeNewswire
Nov-15-18,Endologix Honors Innovators of Aortic Therapy at VEITHsymposium,Business Wire
Dec-13-18,Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),Business Wire
Dec-20-18,"Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference",Business Wire
Dec-21-18,"What Kind Of Shareholder Owns Most Endologix, Inc. (NASDAQ:ELGX) Stock?",Simply Wall St.
Jan-04-19,Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications,Business Wire
Jan-07-19,Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance,Business Wire
